Takeda Pharmaceutical Company Limited (LON: 0A87)

London flag London · Delayed Price · Currency is GBP · Price in USD
13.12
+0.10 (0.77%)
At close: Dec 20, 2024
-4.93%
Market Cap 33.24B
Revenue (ttm) 23.68B
Net Income (ttm) 1.51B
Shares Out n/a
EPS (ttm) 0.95
PE Ratio 22.01
Forward PE n/a
Dividend n/a
Ex-Dividend Date Sep 30, 2024
Volume 270
Open 13.04
Previous Close 13.02
Day's Range 13.02 - 13.12
52-Week Range 10.01 - 11.99
Beta n/a
Analysts n/a
Price Target n/a
Earnings Date Jan 30, 2025

About Takeda Pharmaceutical Company

Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, immunology, oncology, and neuroscience. The company provides its products under the Entyvio, Gattex/Revestive, Takecab/Vocinti, EOHILIA, Alofisel, Dexilant, Pantoloc/Controloc, Adynovate/Adynovi, Feiba, Recombinate, Hemofil/Immunate/Immunine, Takhzyro, Livtencity, A... [Read more]

Industry Pharmaceutical Preparations
Founded 1781
Employees 49,281
Stock Exchange London Stock Exchange
Ticker Symbol 0A87
Full Company Profile

Financial Performance

In 2023, Takeda Pharmaceutical Company's revenue was 4.26 trillion, an increase of 5.87% compared to the previous year's 4.03 trillion. Earnings were 144.07 billion, a decrease of -54.56%.

Financial numbers in JPY Financial Statements

News

There is no news available yet.